New York – October 27, 2026 -- ProJenX will present long-term Phase 1b data at the 2026 NEALS Annual Meeting showing that its ALS candidate prosetin reached target therapeutic exposures and kept a favorable safety profile over extended dosing. The meeting runs Oct. 27-30 in Clearwater, Florida, and online.